HROW icon

Harrow
HROW

35.23 USD
+0.32
0.92%
At close Updated Mar 17, 4:00 PM EDT
Pre-market
After hours
35.60
+0.37
1.05%
1 day
0.92%
5 days
-0.9%
1 month
-30.29%
3 months
-20.64%
6 months
-18.35%
Year to date
-29.41%
1 year
51.07%
5 years
357.53%
10 years
748.92%
 

About: Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Employees: 373

Healthcare Drug Manufacturers - Specialty & Generic
0
Funds holding %
of 8,085 funds
Explore Fund Trends
0
Analysts bullish %
of 2 analysts
See Analyst Outlook
0
Positive news %
of 13 articles
Check Journalist POV
Price charts implemented using Lightweight Charts™